Clinical trials: Biliary Cancers
Biliary Tract Cancer
HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
This is a single-arm, exploratory, phase II trial to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy combined with adebrelimab and lenvatinib for borderline resectable, locally advanced biliary tract…
- Trial name
- NCT06389500
- Testing
- Adebrelimab, Lenvatinib, Hepatic Arterial Infusion Chemotherapy
- Volunteers
- 30 people
- Sponsor
- Harbin Medical University
Jaundice, Obstructive, Cholangiopancreatography, Endoscopic Retrograde
A RCT of Low MBO Drainage Strategies
The purpose of this study is to evaluate the efficacy and safety of EUS-BD compared with ERCP-BD in low biliary obstruction caused by periampullary cancer, pancreatic cancer or low bile duct cancer.
- Conditions
- Jaundice, Obstructive, Cholangiopancreatography, Endoscopic Retrograde, Endoscopic Ultrasound-Guided Drainage
- Trial name
- NCT06196164
- Testing
- EUS-BD, ERCP-BD
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Carcinoma
Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer
The purpose of this study is to demonstrate that preoperative biliary drainage using self-expanding metal stents (SEMS) does not negatively impact overall surgical outcomes in patients undergoing pancreaticoduodenectomy for…
- Trial name
- NCT01774019
- Testing
- WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
- Where
- 11 sites in United States, Australia and 7 more
- Volunteers
- 284 people
- Sponsor
- Boston Scientific Corporation
Pancreatic Ductal Adenocarcinoma, Liver, Cancer of, Primary Resectable
Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery
The goal of this study is to assess the efficacy of intraoperative celiac plexus block (CPB) to reduce opioid consumption following laparoscopic hepato-pancreato-biliary surgery
- Trial name
- CEBOIDS (NCT06214533)
- Testing
- Ropivacaine 0.5%, Normal Saline
- Volunteers
- 60 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Pancreatic Neoplasms, Biliary Tract Neoplasms
Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy
The purpose of this study is to determine whether duct-to-mucosa is better than invagination in pancreaticojejunostomy after pancreaticoduodenectomy.
- Trial name
- NCT01695447
- Testing
- duct-to-mucosa, invagination, Internal stent
- Where
- China
- Volunteers
- 100 people
- Sponsor
- TingBo Liang
Biliary Tract Cancer (BTC)
Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers
The goal of this clinical trial is to etablish whether adding Mitazalimab to standard chemotherapy is more effective than standard chemotherapy alone in people with advanced bile duct cancer.
- Trial name
- CROCOBIL (NCT07437287)
- Testing
- mFOLFOX regimen, Mitazalimab
- Where
- 22 sites in France
- Volunteers
- 160 people
- Sponsor
- UNICANCER
Biliary Track Cancer
Histotripsy in Biliary Tract Cancer
The purpose of this pilot study is to examine the safety and feasibility of histotripsy in two cohorts of 12 patients each with Biliary Track Cancer (BTC), with a plan to expand to a larger multi-center study if both safety and…
- Trial name
- NCT07853690
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NYU Langone Health
Advanced Biliary Tract Carcinoma
Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
This is a phase II open-label, one-arm, multicenter study aimed to explore the efficacy and safety of perioperative (neoadjuvant and adjuvant) treatment for patients with advanced biliary tract carcinoma.
- Trial name
- NCT05451290
- Testing
- Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Pancreatic Cancer
Preoperative Biliary Drainage in Malignant Biliary Obstruction
The first alarming symptom of a malignancy of the pancreas or periampullary tumor can be obstructive jaundice (OJ). Pancreato-duodenectomy (PD) combined with oncological treatment can provide long disease-free survival in…
- Trial name
- PEAR (NCT04847297)
- Testing
- Preoperative drainage and pancreatoduodenectomy, Pancreatoduodenectomy
- Volunteers
- 353 people
- Sponsor
- University of Pecs
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Bile Duct Carcinoma, Cholangiocarcinoma
Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study
This study is a prospective, multicenter, open-label, umbrella phase II clinical trial. Based on different multigene expression profiling subtypes and potential molecular characteristics of various pathways, 8 treatment arms and…
- Trial name
- NCT07729917
- Testing
- FGFR Inhibitor, IDH1 mutation inhibitor, KRAS mutation inhibitor
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Zhejiang University
Biliary Tract Cancer
XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors
The main purpose of this study is to determine if XL119 is more effective than the combination of 5-fluorouracil (5FU) and leucovorin (LV) in prolonging the survival of subjects with advanced biliary tumors.
- Trial name
- NCT00090025
- Testing
- becatecarin, 5-Fluorouracil Plus Leucovorin
- Where
- 59 sites in United States, Belgium and 9 more
- Volunteers
- 248 people
- Sponsor
- Helsinn Healthcare SA
Periampullary Cancers With Obstructive Jaundice, Pancreas Head Cancer
Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers
Preoperative biliary drainage methods include percutaneous transhepatic biliary drainage (PTBD), endoscopic nasobiliary drainage (ENBD), and endoscopic retrograde biliary drainage (ERBD).
- Conditions
- Periampullary Cancers With Obstructive Jaundice, Pancreas Head Cancer, Bile Duct Cancer, Ampulla of Vater Cancer
- Trial name
- NCT01134276
- Testing
- biliary drainage
- Where
- South Korea
- Volunteers
- 211 people
- Sponsor
- Seoul National University Hospital
Ovarian Cancer, Cholecystolithiasis
Safety of Opportunistic Salpingectomy During Elective Laparoscopic Cholecystectomy.
The knowledge, coupled with epidemiological studies demonstrating lower ovarian cancer rates in women with a history of tubal sterilization has led to recommendations for opportunistic salpingectomy at the time of benign…
- Trial name
- NCT07642791
- Testing
- Opportunistic salpingectomy, Cholecystectomy
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- University of Zurich
Biliary Tract Adenocarcinoma
Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma
The prospective, multicenter, single-arm design study is to evaluate the efficacy and safety of fruquintinib for patients with advanced or metastatic biliary tract adenocarcinoma who failed first-line chemotherapy with…
- Trial name
- FSTAMBTA (NCT04156958)
- Testing
- Fruquintinib
- Where
- 7 sites in China
- Volunteers
- 33 people
- Sponsor
- Sichuan University
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, cisplatin, oxaliplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00304135
- Testing
- cisplatin, gemcitabine hydrochloride, oxaliplatin
- Where
- 20 sites in France
- Volunteers
- 34 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Biliary Tract Cancer
Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas
This Phase II clinical trial is to study the effectiveness and safety of continuous hepatic arterial infusion (HAI) of Oxaliplatin and Fluorouracil in Patients with Unresectable Biliary tract carcinomas, and to explore a better…
- Trial name
- NCT01572324
- Testing
- Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Peking University
Biliary Tract Cancer
Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer
To evaluate the efficacy and safety of Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin Compared With Gemcitabine +Cisplatin as First-line Chemotherapy for Unresectable or Metastatic Biliary Tract…
- Trial name
- NCT04300959
- Testing
- Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin, Gemcitabine Plus(+)Cisplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhejiang Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.